Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SPHK1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SPHK1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SPHK1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SPHK1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SPHK1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SPHK1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SPHK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190332017 | Endometrium | EEC | regulation of protein modification by small protein conjugation or removal | 72/2168 | 242/18723 | 1.45e-14 | 4.36e-12 | 72 |
GO:003139617 | Endometrium | EEC | regulation of protein ubiquitination | 62/2168 | 210/18723 | 1.42e-12 | 2.76e-10 | 62 |
GO:000697917 | Endometrium | EEC | response to oxidative stress | 99/2168 | 446/18723 | 9.02e-11 | 1.13e-08 | 99 |
GO:006219717 | Endometrium | EEC | cellular response to chemical stress | 77/2168 | 337/18723 | 2.87e-09 | 2.10e-07 | 77 |
GO:000030217 | Endometrium | EEC | response to reactive oxygen species | 57/2168 | 222/18723 | 4.04e-09 | 2.82e-07 | 57 |
GO:004254216 | Endometrium | EEC | response to hydrogen peroxide | 41/2168 | 146/18723 | 4.12e-08 | 2.29e-06 | 41 |
GO:001604915 | Endometrium | EEC | cell growth | 95/2168 | 482/18723 | 1.16e-07 | 5.54e-06 | 95 |
GO:003806612 | Endometrium | EEC | p38MAPK cascade | 21/2168 | 55/18723 | 3.30e-07 | 1.33e-05 | 21 |
GO:005140314 | Endometrium | EEC | stress-activated MAPK cascade | 55/2168 | 239/18723 | 3.98e-07 | 1.56e-05 | 55 |
GO:003459917 | Endometrium | EEC | cellular response to oxidative stress | 63/2168 | 288/18723 | 4.05e-07 | 1.58e-05 | 63 |
GO:003109814 | Endometrium | EEC | stress-activated protein kinase signaling cascade | 56/2168 | 247/18723 | 5.25e-07 | 2.00e-05 | 56 |
GO:003287214 | Endometrium | EEC | regulation of stress-activated MAPK cascade | 46/2168 | 192/18723 | 1.06e-06 | 3.56e-05 | 46 |
GO:007030214 | Endometrium | EEC | regulation of stress-activated protein kinase signaling cascade | 46/2168 | 195/18723 | 1.67e-06 | 5.12e-05 | 46 |
GO:190074411 | Endometrium | EEC | regulation of p38MAPK cascade | 18/2168 | 47/18723 | 2.16e-06 | 6.41e-05 | 18 |
GO:004341011 | Endometrium | EEC | positive regulation of MAPK cascade | 89/2168 | 480/18723 | 4.21e-06 | 1.08e-04 | 89 |
GO:003461416 | Endometrium | EEC | cellular response to reactive oxygen species | 37/2168 | 155/18723 | 1.26e-05 | 2.55e-04 | 37 |
GO:000155814 | Endometrium | EEC | regulation of cell growth | 77/2168 | 414/18723 | 1.64e-05 | 3.16e-04 | 77 |
GO:003010014 | Endometrium | EEC | regulation of endocytosis | 45/2168 | 211/18723 | 3.40e-05 | 5.78e-04 | 45 |
GO:190332213 | Endometrium | EEC | positive regulation of protein modification by small protein conjugation or removal | 33/2168 | 138/18723 | 3.49e-05 | 5.90e-04 | 33 |
GO:003139813 | Endometrium | EEC | positive regulation of protein ubiquitination | 29/2168 | 119/18723 | 7.05e-05 | 1.04e-03 | 29 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0407116 | Esophagus | ESCC | Sphingolipid signaling pathway | 85/4205 | 121/8465 | 3.04e-06 | 1.73e-05 | 8.84e-06 | 85 |
hsa051527 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
hsa0466620 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
hsa006003 | Esophagus | ESCC | Sphingolipid metabolism | 36/4205 | 53/8465 | 5.41e-03 | 1.36e-02 | 6.99e-03 | 36 |
hsa0407117 | Esophagus | ESCC | Sphingolipid signaling pathway | 85/4205 | 121/8465 | 3.04e-06 | 1.73e-05 | 8.84e-06 | 85 |
hsa0515212 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
hsa04666110 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
hsa0060012 | Esophagus | ESCC | Sphingolipid metabolism | 36/4205 | 53/8465 | 5.41e-03 | 1.36e-02 | 6.99e-03 | 36 |
hsa040718 | Liver | HCC | Sphingolipid signaling pathway | 72/4020 | 121/8465 | 5.01e-03 | 1.47e-02 | 8.18e-03 | 72 |
hsa0466610 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
hsa00600 | Liver | HCC | Sphingolipid metabolism | 34/4020 | 53/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 34 |
hsa0407111 | Liver | HCC | Sphingolipid signaling pathway | 72/4020 | 121/8465 | 5.01e-03 | 1.47e-02 | 8.18e-03 | 72 |
hsa0466611 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
hsa006001 | Liver | HCC | Sphingolipid metabolism | 34/4020 | 53/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 34 |
hsa0407114 | Oral cavity | OSCC | Sphingolipid signaling pathway | 82/3704 | 121/8465 | 6.97e-08 | 5.08e-07 | 2.58e-07 | 82 |
hsa051526 | Oral cavity | OSCC | Tuberculosis | 105/3704 | 180/8465 | 5.00e-05 | 2.04e-04 | 1.04e-04 | 105 |
hsa0466618 | Oral cavity | OSCC | Fc gamma R-mediated phagocytosis | 60/3704 | 97/8465 | 2.35e-04 | 7.72e-04 | 3.93e-04 | 60 |
hsa04370 | Oral cavity | OSCC | VEGF signaling pathway | 37/3704 | 59/8465 | 2.53e-03 | 6.62e-03 | 3.37e-03 | 37 |
hsa006002 | Oral cavity | OSCC | Sphingolipid metabolism | 33/3704 | 53/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 33 |
hsa0407115 | Oral cavity | OSCC | Sphingolipid signaling pathway | 82/3704 | 121/8465 | 6.97e-08 | 5.08e-07 | 2.58e-07 | 82 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPHK1 | SNV | Missense_Mutation | rs149492135 | c.1055N>T | p.Ser352Leu | p.S352L | Q9NYA1 | protein_coding | deleterious(0) | possibly_damaging(0.755) | TCGA-A7-A26E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
SPHK1 | deletion | Frame_Shift_Del | | c.290_303delTCCCGCGGCCCTGC | p.Leu97ProfsTer29 | p.L97Pfs*29 | Q9NYA1 | protein_coding | | | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SPHK1 | SNV | Missense_Mutation | rs866618568 | c.812N>A | p.Arg271Gln | p.R271Q | Q9NYA1 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SPHK1 | SNV | Missense_Mutation | | c.961G>C | p.Asp321His | p.D321H | Q9NYA1 | protein_coding | deleterious(0.03) | possibly_damaging(0.847) | TCGA-DS-A0VN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
SPHK1 | SNV | Missense_Mutation | novel | c.510G>A | p.Met170Ile | p.M170I | Q9NYA1 | protein_coding | tolerated(0.24) | benign(0.003) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SPHK1 | deletion | Frame_Shift_Del | | c.1160delG | p.Arg387ProfsTer44 | p.R387Pfs*44 | Q9NYA1 | protein_coding | | | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SPHK1 | SNV | Missense_Mutation | rs773839692 | c.1133N>T | p.Ala378Val | p.A378V | Q9NYA1 | protein_coding | deleterious(0) | benign(0.325) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPHK1 | SNV | Missense_Mutation | rs775563147 | c.255N>T | p.Glu85Asp | p.E85D | Q9NYA1 | protein_coding | tolerated(0.08) | benign(0.06) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPHK1 | SNV | Missense_Mutation | novel | c.713N>C | p.Leu238Pro | p.L238P | Q9NYA1 | protein_coding | deleterious(0) | possibly_damaging(0.637) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPHK1 | SNV | Missense_Mutation | novel | c.1220N>G | p.Tyr407Cys | p.Y407C | Q9NYA1 | protein_coding | tolerated(0.1) | benign(0.047) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | | PMID27539678-Compound-11 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | | ABC294640 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | inhibitor | 404859088 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | | PMID27539678-Compound-13 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | | GSK618334 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | inhibitor | 178103235 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | | PMID27539678-Compound-16 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | | PMID27539678-Compound-7 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | inhibitor | 381744899 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | | Methylbenzenesulfonamide derivative 1 | | |